



# ESMO Preceptorship on Hepatocellular Carcinoma

## PROGRAMME

**ESMO PRECEPTORSHIP**

**MADRID SPAIN  
15-16 DECEMBER 2023**

**Co-Chairs**

Erika Martinelli, Italy  
Arndt Vogel, Germany

# ESMO PRECEPTORSHIP PROGRAMME HEPATOCELLULAR CARCINOMA

Multidisciplinary management, standards of care,  
therapeutic targets and future perspectives

**Madrid, Spain**  
**15-16 December 2023**

---

## CO-CHAIRS

Erika Martinelli, Italy  
Arndt Vogel, Germany

## SPEAKERS

Julien Calderaro, France  
Roeland de Wilde, Netherlands  
John Primrose, United Kingdom  
Maria Reig, Spain  
Jens Ricke, Germany  
Lorenza Rimassa, Italy  
Anna Saborowski, Germany

---

## LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of HCC
- To assess the best treatment according to radiological staging
- To learn about sequencing of treatments with special focus on adverse events

---

## ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano, Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Friday, 15 December 2023

|                           |   |   |
|---------------------------|---|---|
| <b>09:00-09:10</b><br>10' | <b>Opening and welcome</b>  |   |
| 10'                       | Welcome from ESMO - Objectives and scientific introduction  | Erika Martinelli, IT<br>Arndt Vogel, DE                                     |
| <b>09:10-10:25</b><br>75' | <b>SESSION 1</b><br><b>Epidemiology and diagnosis</b>   | <b>Chairs:</b><br><b>Lorenza Rimassa, IT</b><br><b>Arndt Vogel, DE</b>      |
| 20'                       | Epidemiology and surveillance   | Maria Reig, ES  |
| 20'                       | Radiologic criteria for HCC   | Jens Ricke, DE  |
| 20'                       | Pathological criteria for HCC   | Julien Calderaro, FR  |
| 15'                       | Discussion  | All   |
| <b>10:25-10:55</b>        | <b>Coffee break</b>   |   |
| <b>10:55-12:05</b><br>70' | <b>SESSION 2 – Part I</b><br><b>Early stage</b>   | <b>Chairs:</b><br><b>Erika Martinelli, IT</b><br><b>Jens Ricke, DE</b>      |
| 20'                       | Surgical treatment of HCC   | John Primrose, UK   |
| 20'                       | Criteria for liver transplantation  | Roeland de Wilde, NL  |
| 10'                       | Discussion  | All   |
| 20'                       | Participants clinical case discussion (2x10')   | Faculty   |
| <b>12:05-13:15</b><br>70' | <b>SESSION 2 – Part II</b><br><b>Early stage / special situation (mixed tumour and special histology)</b> | <b>Chairs:</b><br><b>Maria Reig, ES</b><br><b>Arndt Vogel, DE</b>           |
| 20'                       | Locoregional treatment  | Lorenza Rimassa, IT   |
| 20'                       | Adjuvant treatment  | Anna Saborowski, DE   |
| 10'                       | Discussion  | All   |
| 20'                       | Participants clinical case discussion (2x10')   | Faculty   |
| <b>13:15-14:15</b>        | <b>Lunch</b>  |   |
| <b>14:15-15:50</b><br>95' | <b>SESSION 3</b><br><b>Intermediate stage</b>   | <b>Chairs:</b><br><b>Erika Martinelli, IT</b><br><b>Anna Saborowski, DE</b> |
| 20'                       | Update on TACE  | Arndt Vogel, DE   |
| 20'                       | Update on SIRT  | Jens Ricke, DE  |
| 20'                       | Ongoing combination trials in intermediate stage  | Erika Martinelli, IT  |
| 15'                       | Discussion  | All   |
| 20'                       | Participants clinical case discussion (2x10')   | Faculty   |
| <b>15:50-16:20</b>        | <b>Coffee break</b>   |   |

|                           |   |   |
|---------------------------|---|---|
| <b>16:20-17:55</b><br>95' | <b>SESSION 4</b><br><b>Advanced stage</b>     | <b>Chairs:</b><br><b>Julien Calderaro, FR</b><br><b>Arndt Vogel, DE</b> |
| 20'                       | First-line therapy                            | Maria Reig, ES  |
| 20'                       | Second-line therapy                           | Anna Saborowski, DE   |
| 20'                       | How to best sequence systemic therapy         | Lorenza Rimassa, IT   |
| 15'                       | Discussion                                    | All   |
| 20'                       | Participants clinical case discussion (2x10') | Faculty   |
| <b>20:00</b>              | <b>Dinner</b>                                 |   |

## Saturday, 16 December 2023

|                           |   |   |
|---------------------------|---|---|
| <b>09:00-10:35</b><br>95' | <b>SESSION 5</b><br><b>Toxicity management</b>              | <b>Chairs:</b><br><b>Maria Reig, ES</b><br><b>Arndt Vogel, DE</b>           |
| 30'                       | IO toxicity   | Arndt Vogel, DE   |
| 30'                       | TKI inhibitors toxicity                                     | Erika Martinelli, IT  |
| 15'                       | Discussion  | All   |
| 20'                       | Participants clinical case discussion (2x10')               | Faculty   |
| <b>10:35-11:05</b>        | <b>Coffee break</b>   |   |
| <b>11:05-11:45</b><br>40' | <b>SESSION 6</b><br><b>Biomarkers and future directions</b> | <b>Chairs:</b><br><b>Erika Martinelli, IT</b><br><b>Lorenza Rimassa, IT</b> |
| 30'                       | Biomarkers and future directions                            | Arndt Vogel, DE   |
| 10'                       | Discussion  | All   |
| <b>11:45-12:00</b><br>15' | <b>Conclusion and farewell</b>                              | <b>Erika Martinelli, IT</b><br><b>Arndt Vogel, DE</b>                       |
| <b>12:00-13:00</b>        | <b>Lunch</b>  |   |

**Note:** Each 10-minute slot for participant clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion